IP Library Granted Patent US 11,426,364
Granted Patent B2
US 11,426,364 · App. 16/751,019 · Granted Aug 30, 2022

Immunomodulator compounds

Inventors: Christopher Lange (El Cerrito, CA); Viengkham Malathong (Mountain View, CA); Darren J. McMurtrie (Sunnyvale, CA); Sreenivas Punna (Sunnyvale, CA); Rajinder Singh (Belmont, CA); Ju Yang (Palo Alto, CA); Penglie Zhang (Foster City, CA)
Assignee: ChemoCentryx, Inc.
A61K31/085A61K31/015A61K31/03A61K31/277A61K38/00A61K45/06A61P29/00A61P31/00A61P35/00C07C43/168C07C215/12C07C229/22C07C235/20C07C235/42C07C255/54C07C317/22C07D205/04C07D211/40C07D213/30C07D213/61C07D213/80C07D213/85C07D237/08C07D239/30C07D239/42C07D319/18C07D401/04C07D401/12C07D401/14C07D405/12C07D405/14C07D409/12C07D413/12C07D417/12C07F5/025C07F9/58A61K31/36A61K31/44A61K31/505A61K47/34C07C2601/02C07C2602/08Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,426,364
App. No.
16/751,019
Granted
Aug 30, 2022
Kind
B2
Abstract

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R 1 , R 2a , R 2b , R 2c , R 3 , R 4 , R 5 , R 6a , R 6b , m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Claims (11)

1. A method of inhibiting growth, proliferation, or metastasis of cancer cells in a subject in need thereof, wherein the cancer cells are selected from the group consisting of colorectal cancer, mesothelioma; breast cancer, colorectal cancer, carcinoma of the endometrium, cancer of the esophagus, small cell lung cancer, renal cell carcinoma, Merkel cell carcinoma, hepatocellular carcinoma, primary mediastinal large B cell lymphoma; carcinoma of the cervix, gastric cancer, cancer of the bladder, classical Hodgkin's lymphoma, head and neck squamous cell carcinoma, and non-small cell lung cancer, comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of

2. The method of claim 1 , wherein the compound is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound has the formula:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound has the formula:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the compound has the formula:

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the compound has the formula:

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNEE CHANGE OF ADDRESS Recorded Jun 27, 2023
From: CHEMOCENTRYX, INC.
To: CHEMOCENTRYX, INC.
Reel/Frame 064144/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2020
From: LANGE, CHRISTOPHER; MALATHONG, VIENGKHAM; MCMURTRIE, DARREN J.; PUNNA, SREENIVAS; SINGH, RAJINDER; YANG, JU; ZHANG, PENGLIE
To: CHEMOCENTRYX, INC.
Reel/Frame 053573/0470 →
Continuity (4)
Division 15633569 · Jun 26, 2017
Provisional Application 62355119 · Jun 27, 2016
Provisional Application 62440100 · Dec 29, 2016
Related Publication 20210052514A1 · Feb 25, 2021
Cited By (3)
US 12,371,433 US 12,497,383 US 12,533,354